Amendments to the claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

1-54. (Cancelled).

55. (New) A process for preparing a pharmaceutical unit dose composition comprising 2 to 8 mg 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy] benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:

(i) preparing a first composition comprising 5 to 20% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier;

(ii) admixing the first composition with at least one pharmaceutically acceptable carrier; and

(iii) formulating the composition produced in step (ii) into said pharmaceutical unit dose composition.

56. (New) A process according to claim 55, wherein the pharmaceutical unit dose composition is a tablet.

57. (New) A process according to claim 55, wherein the first composition is in granular form.

58. (New) A process according to claim 55, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

59. (New) A process according to claim 55, wherein the first composition contains 15% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

60. (New) A process according to claim 57, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

61. (New) A process according to claim 55, wherein the first composition contains 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form, sodium starch glycollate, hydroxypropyl methylcellulose 2910, microcrystalline cellulose and lactose monohydrate.

62. (New) A process according to claim 61, wherein the first composition is in granular form.

63. (New) A process according to claim 62, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

64. (New) A process according to claim 55, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable salt.

65. (New) A process according to claim 64, wherein the salt is a maleate salt.

66. (New) A process according to claim 55, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable solvate.

67. (New) A process according to claim 66, wherein the solvate is a hydrate.

68. (New) A process according to claim 55, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.

69. (New) A process according to claim 55, wherein the pharmaceutical unit dose composition comprises 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

70. (New) A process according to claim 55, wherein the pharmaceutical unit dose composition comprises 4 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

71. (New) A process according to claim 55, wherein the pharmaceutical unit dose composition comprises 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

72. (New) A pharmaceutical composition formed by the process of claim 55.

73. (New) A pharmaceutical composition formed by the process of claim 63.

74. (New) A pharmaceutical composition formed by the process of claim 65.

75. (New) A process for preparing a pharmaceutical unit dose composition comprising 1 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:

(i) preparing a first composition comprising 5 to 20% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier;

(ii) admixing the first composition with at least one pharmaceutically acceptable carrier; and

(iii) formulating the composition produced in step (ii) into said pharmaceutical unit dose composition.

76. (New) A process according to claim 75, wherein the pharmaceutical unit dose composition is a tablet.

77. (New) A process according to claim 75, wherein the first composition is in granular form.

78. (New) A process according to claim 75, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

79. (New) A process according to claim 77, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

80. (New) A process according to claim 75, wherein the first composition contains 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form, sodium starch glycollate, hydroxypropyl methylcellulose 2910, microcrystalline cellulose and lactose monohydrate.

81. (New) A process according to claim 80, wherein the first composition is in granular form.

82. (New) A process according to claim 81, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

83. (New) A process according to claim 75, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable salt.

84. (New) A process according to claim 83, wherein the salt is a maleate salt.

85. (New) A process according to claim 75, wherein the pharmaceutical unit dose composition comprises 1 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

86. (New) A pharmaceutical composition formed by the process of claim 75.

87. (New) A pharmaceutical composition formed by the process of claim 82.

88. (New) A pharmaceutical composition formed by the process of claim 84.